Laekna (HKG:2105) completed patient enrollment in the phase 3 clinical trial of LAE002 to treat breast cancer, according to a Hong Kong bourse filing Monday.

The late-stage trial, called AFFIRM-205, will study LAE002 in combination with fulvestrant. Topline data is expected in the first half of 2026, followed by a new drug application with Chinese regulators later in the year, the firm said.